Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
YZiLabs: Plans to Expand the BNC Board of Directors

YZiLabs: Plans to Expand the BNC Board of Directors

金色财经金色财经2025/11/27 22:44
Show original

Jinse Finance reported that YZiLabs has submitted a preliminary consent statement to the US SEC, proposing to expand the board size of Nasdaq-listed company CEA Industries Inc. (BNC) and elect several new directors through a written shareholder consent solicitation. YZiLabs stated that its investment in BNC is based on confidence in the company's fundamentals, its BNB-centric Digital Asset Treasury (DAT) strategy, and its potential to become a "category-defining DAT company." However, since completing a $500 million PIPE financing this summer, BNC's stock price performance has clearly diverged from this logic, even though BNB's price has seen a considerable increase during the same period. YZiLabs said it will soon announce the specific list of board candidates, aiming to unlock the company's potential value through stronger board governance without undermining BNC's Digital Asset Treasury vision.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%